

REMARKS/ARGUMENTS


Claims 1, 3 and 22-30 are now pending. Claim 2 has been cancelled, and new claims 22-30 have been added. Support for the new claims appears, for example, in the originally filed claims, and on pages 13, 14 and 17 of the specification. Applicants reserve the right to pursue any previously claimed subject matter in one or more continuation or divisional applications.

In the outstanding Office Action, the Examiner has imposed an election of species of secretory phospholipase A2 inhibitor, referring to the disclosure on page 17 of the specification.

Applicants elect the species of oleyloxyethylphosphocholine. Claims readable on the elected species include claims 1, 3, and 22-30. Examination of the amended claims is respectfully requested.

The Commissioner is authorized to charge any additional fees to Deposit Account 11-0980.

Respectfully submitted,



Madeline I. Johnston, Esq.
Registration No. 36,174

June 13, 2006
King & Spalding, LLP
1180 Peachtree Street
Atlanta, GA 30309-3521
(404) 572-4720